USP1 and cancer: Additionally, considering our result that combined SPRTN depletion and ML323 treatment augments the cytotoxicity induced by cisplatin (Fig. 5f), this raises the possibility that the expression level of SPRTN (and possibly other DNA-dependent proteases) may be a useful biomarker to determine the potential effectiveness of using USP1 inhibitors in cancer treatment.